Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infection.
Muñoz Sandoval D. et al, (2025), J Exp Med, 222
Diagnosis of Plasmodium falciparum malaria at very low parasitaemias using a commercially available LAMP assay and RDT.
Payne RO. et al, (2025), Trans R Soc Trop Med Hyg
Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.
Thiam LG. et al, (2024), NPJ Vaccines, 9
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.
Wang LT. et al, (2024), Cell, 187, 4981 - 4995.e14
Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5.
Harrison TE. et al, (2024), EMBO Mol Med
Plug and play virus-like particles for the generation of anti-toxin antibodies.
Edge RJ. et al, (2024), Toxicon X, 23
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
King LDW. et al, (2024), Cell Rep Med, 5
Structure-guided design of aPlasmodium vivaxDuffy binding protein-based vaccine immunogen
Barber NM. et al, (2024)
Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
Mertens JE. et al, (2024), Vaccine, 42, 3621 - 3629
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.
Williams BG. et al, (2024), Nat Commun, 15
PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.
Martinez FJ. et al, (2024), NPJ Vaccines, 9
Adeno-associated viral vectored delivery of monoclonal antibody genes against blood-stage malaria
Bardelli M. et al, (2024), HUMAN GENE THERAPY, 35, A130 - A131